ClinicalTrials.gg
CompletedNCT02097056SAVEUpdated Jun 27, 2016Results posted

Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease

A Phase 4 interventional study of Donepezil HCL in Alzheimer's Disease, sponsored by Eisai Korea Inc.. Completed at 13 sites in Korea, Republic of. Open to participants aged 45 Years to 90 Years. Per ClinicalTrials.gov, last updated 2016-06-27.

Sponsored by Eisai Korea Inc. (part of Eisai Co., Ltd.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
171
Allocation
Not applicable
Ages
45 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing donepezil in Alzheimer Disease — 2 open to participants now, 2 under way, 1 of them phase 3. Donepezil · Alzheimer Disease.

Enrollment
18th of 58
171 · median 79
Started
2014
with 5 others
Phase 4
20 of 60
none open now
Registered
42nd of 60
by date
Lead sponsor
4 of 60
Eisai Korea Inc.

Among the 60 studies testing donepezil in Alzheimer Disease, this one is the 18th largest by enrollment of the 58 interventional ones that give a count, is one of 6 that started in 2014, is one of 20 in phase 4, and was the 42nd registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

2 of the 60 studies testing donepezil in Alzheimer Disease are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About donepezil

Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 45 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing donepezil in Alzheimer Disease, or all of them as a file.
02

Study summary

This is a multi-center, open-label, single-arm, prospective, phase IV trial, evaluating safety and efficacy of donepezil hydrochloride in patients with moderate to severe Alzheimer's disease.

Read the detailed description

This study consisted of pre-treatment and treatment phase. Pre-treatment phase was approximately 4 weeks including the screening and baseline process. In treatment phase, about 190 subjects received Donepezil HCl 23 mg once daily for 24 weeks.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

Keywords

  • Alzheimer's disease
04

Who can participate

Ages eligible
45 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged 45 to 90 years
  2. Patients have eligible conditions of dementia diagnosis listed in
  3. Diagnosed as a probable Alzheimer's Disease patient according to NINCDS-ADRDA criteria
  4. At the timing of screening, less than or equal to 20 AND CDR greater than or equal to 2 OR GDS greater than or equal to 4
  5. Patients, who have been taking stable donepezil 10 mg for 3 months or longer before the start of the study (screening visit), are evaluated as eligible to take donepezil 23 mg by investigator
  6. Patients who have not received any other medications for AD such as AChE inhibitors at least for 3 months prior to the screening visit excluding donepezil hydrochloride (However, concomitant use of memantine is allowed if taken at stable dose that are less than or equal to the approved dose range for at least 3 months prior to screening)
  7. Medicines for cerebral activation such as Gingko Biloba is allowed to be taken if the patient has received it as stable dose for 3 months prior to the screening visit

Exclusion criteria

Exclusion Criteria

  1. Patients who have been participated in any other clinical trial 3 months prior to the screening visit
  2. Patients who are having any severe psychiatric disorder or schizophrenia
  3. Patients who are having a neurological disorder other than AD which affect the subject's cognition or ability to assess the cognition
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
171 participants (actual)

Study arms

  • Experimental
    donepezil HCl 23 mg

    Donepezil HCl 23 mg once daily, just before bed, for 24 weeks

    Drug: Donepezil HCL

Interventions

  • Donepezil HCl 23 mg once daily, just before bed, for 24 weeks

06

What researchers measure

Primary outcomes

  1. Overall Summary of Adverse Events (AEs)

    Safety of study drug was assessed by clinical laboratory assessments, vital signs, weight, 12-lead electrocardiogram (ECG), physical and neurological examination. Treatment-Emergent Adverse Events (TEAEs) were defined as any event not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. Serious adverse events were defined as AEs that led to or were life-threatening, resulted in or prolonged hospitalization, caused important or long-lasting disability, caused congenital abnormality or malformation, or resulted in death. Adverse drug reactions were defined as any harmful or unintended reaction to study treatment and were considered possibly related or probably related to study drug. Specific AEs and SAEs due to changes in clinical laboratory assessments, vital signs, weight, ECG, and physical and neurological exam are listed in the safety section.

    Time frame: Baseline (Day 1) up to Week 24

Secondary outcomes

  1. Change From Baseline in the Mini-Mental State Examination (MMSE) Score

    The MMSE was used to measure cognitive impairment. The MMSE can evaluate overall cognitive function, and is widely used for the assessment of cognitive impairment in dementia patients. The questionnaire consists of 11 items, and each item aims to evaluate different cognitive domains such as orientation, memory, attention, and construction. The score ranged from 0 to 30, with a higher score indicating better function. A positive change score indicated improvement from baseline. The mean change was analyzed by Wilcoxon's signed rank test.

    Time frame: Baseline, Week 12, and Week 24 (Final visit)

  2. Change From Baseline in the Neuropsychiatric Inventory Questionnaire (NPI-Q) Severity and Distress Total Scores

    The NPI-Q assessed twelve behavioral domains common in dementia including; hallucinations, delusions, agitation/aggression, dysphoria/depression, anxiety, irritability, disinhibition, euphoria, apathy, aberrant motor behavior, sleep/night-time behavior change, and appetite/eating change. The questionnaire is given by the clinician to the patient's caregiver who was asked if the behavior described is present in the patient. If "Yes", the informant then rates both the Severity of the symptoms present within the last month on a 3-point scale (1 = mild, 2= moderate, and 3= severe) and the associated impact of the symptom manifestations on them (i.e. Caregiver Distress) using a 5-point scale (0 = not distressing at all, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = extreme or very severe). The total severity score represents the sum of individual scores and ranges from 0 to 36. The total distress score represents the sum of individual symptom scores and ranges from 0 to 60.

    Time frame: Baseline, Week 12, and Week 24 (Follow up visit)

07

Results

Posted Jun 27, 2016

Participant flow

Participant flow — Overall Study
MilestoneDonepezil Hydrochloride
Started171
Participantstreated170
Completed113
Not completed58
Withdrew: Protocol violation2
Withdrew: Withdrawal by subject15
Withdrew: Lost to follow-up2
Withdrew: Adverse event37
Withdrew: Other2

Outcome measures

PrimaryOverall Summary of Adverse Events (AEs)

Safety of study drug was assessed by clinical laboratory assessments, vital signs, weight, 12-lead electrocardiogram (ECG), physical and neurological examination. Treatment-Emergent Adverse Events (TEAEs) were defined as any event not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. Serious adverse events were defined as AEs that led to or were life-threatening, resulted in or prolonged hospitalization, caused important or long-lasting disability, caused congenital abnormality or malformation, or resulted in death. Adverse drug reactions were defined as any harmful or unintended reaction to study treatment and were considered possibly related or probably related to study drug. Specific AEs and SAEs due to changes in clinical laboratory assessments, vital signs, weight, ECG, and physical and neurological exam are listed in the safety section.

Time frame:
Baseline (Day 1) up to Week 24
Reported as:
Number · Percentage of participants
Overall Summary of Adverse Events (AEs)
Percentage of participantsDonepezil Hydrochloride
AEs67.65
ADRs47.06
SAEs7.06
Serious ADRs0.59
SecondaryChange From Baseline in the Mini-Mental State Examination (MMSE) Score

The MMSE was used to measure cognitive impairment. The MMSE can evaluate overall cognitive function, and is widely used for the assessment of cognitive impairment in dementia patients. The questionnaire consists of 11 items, and each item aims to evaluate different cognitive domains such as orientation, memory, attention, and construction. The score ranged from 0 to 30, with a higher score indicating better function. A positive change score indicated improvement from baseline. The mean change was analyzed by Wilcoxon's signed rank test.

Time frame:
Baseline, Week 12, and Week 24 (Final visit)
Reported as:
Mean · Scores on a scale
Change From Baseline in the Mini-Mental State Examination (MMSE) Score
Scores on a scaleDonepezil Hydrochloride
Change W12-0.31 ± 2.76
Change W24-0.40 ± 2.75
SecondaryChange From Baseline in the Neuropsychiatric Inventory Questionnaire (NPI-Q) Severity and Distress Total Scores

The NPI-Q assessed twelve behavioral domains common in dementia including; hallucinations, delusions, agitation/aggression, dysphoria/depression, anxiety, irritability, disinhibition, euphoria, apathy, aberrant motor behavior, sleep/night-time behavior change, and appetite/eating change. The questionnaire is given by the clinician to the patient's caregiver who was asked if the behavior described is present in the patient. If "Yes", the informant then rates both the Severity of the symptoms present within the last month on a 3-point scale (1 = mild, 2= moderate, and 3= severe) and the associated impact of the symptom manifestations on them (i.e. Caregiver Distress) using a 5-point scale (0 = not distressing at all, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = extreme or very severe). The total severity score represents the sum of individual scores and ranges from 0 to 36. The total distress score represents the sum of individual symptom scores and ranges from 0 to 60.

Time frame:
Baseline, Week 12, and Week 24 (Follow up visit)
Reported as:
Mean · Scores on a scale
Change From Baseline in the Neuropsychiatric Inventory Questionnaire (NPI-Q) Severity and Distress Total Scores
Scores on a scaleDonepezil Hydrochloride
Change Week 12 (Severity)0.33 ± 4.74
Change Week 24 (Severity)0.09 ± 5.67
Change Week 12 (Distress)0.19 ± 6.83
Change Week 24 (Distress)0.29 ± 7.60

Adverse events

Collected over AEs were collected from Day 1 through Week 24 of study.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Donepezil Hydrochloride—12/170 (7.1%)109/170 (64.1%)
Most frequent serious events
Most frequent serious events
EventDonepezil Hydrochloride
Femur fractureInjury, poisoning and procedural complications2/170
Rib fractureInjury, poisoning and procedural complications2/170
Ankle fractureInjury, poisoning and procedural complications1/170
Cervical vertebral fractureInjury, poisoning and procedural complications1/170
Ligament injuryInjury, poisoning and procedural complications1/170
Lumbar vertebral fractureInjury, poisoning and procedural complications1/170
DiarrhoeaGastrointestinal disorders1/170
Gait disturbanceGeneral disorders1/170
PneumoniaInfections and infestations1/170
Decreased appetiteMetabolism and nutrition disorders1/170
Most frequent other events
Showing 10 of 85
Most frequent other events
EventDonepezil Hydrochloride
NauseaGastrointestinal disorders21/170
VomitingGastrointestinal disorders19/170
Decreased appetiteMetabolism and nutrition disorders16/170
DizzinessNervous system disorders13/170
DiarrhoeaGastrointestinal disorders11/170
LethargyNervous system disorders8/170
HeadacheNervous system disorders6/170
SomnolenceNervous system disorders6/170
AnxietyPsychiatric disorders6/170
Urinary incontinenceRenal and urinary disorders6/170

Baseline characteristics

Safety population included all participants who received at least one dose of study treatment and had at least one postbaseline safety assessment.

Age, Continuous
Age, Continuous(Years)Donepezil Hydrochloride
Mean74.82 ± 7.18
Sex: Female, Male
Sex: Female, Male(Participants)Donepezil Hydrochloride
Female123
Male47
08

Study locations

13 sites
  • Chungju, Chungcheongbuk-do, Korea, Republic of
  • Ansan, Gyeonggi-do, Korea, Republic of
  • Buchoen, Gyeonggi-do, Korea, Republic of
  • Seongnam, Gyeonggi-do, Korea, Republic of
  • Jinju, Gyeongsangnam-do, Korea, Republic of
  • Iksan, Jeollabuk-do, Korea, Republic of
  • Hwasun, Jeollanam-do, Korea, Republic of
  • Busan, Korea, Republic of
  • Daegu, Korea, Republic of
  • Daejeon, Korea, Republic of
  • Incheon, Korea, Republic of
  • Jeju, Korea, Republic of
  • Seoul, Korea, Republic of
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2014, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2014
First posted
Mar 26, 2014
Start
Feb 2014
Primary completionActual
May 2015
CompletionActual
May 2015
Results first posted
Jun 27, 2016
Last update
Jun 27, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02097056
Lead sponsor
Eisai Korea Inc.
Responsible party
Sponsor
First posted
Mar 26, 2014
Start date
Feb 2014
Primary completion
May 2015
Completion
May 2015
Results posted
Jun 27, 2016
Last update
Jun 27, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion